https://www.delveinsight.com/asco-conference/article/elranatamab-exhibits-asco?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

1. MULTIPLE MYELOMA ASCO CONFERENCE 2022
MULTIPLE MYELOMA
Elranatamab exhibits a 60.6% ORR and a tolerable
safety profile, according to new results from a
planned interim analysis of the Phase II
MagnetisMM-3 registration-enabling study
Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase II MagnetisMM-
3 Trial of BCMA-CD3 Bispecific Antibody elranatamab (PF-06863135)
Mechanism of Action: Binds BCMA on myeloma cells and CD3 T cells, thereby bringing
together T cells and activating them in the vicinity of the myeloma cell resulting in cell kill.
Main Content- Elranatamab is a BCMA x CD3-targeted investigational therapy currently
being developed to treat multiple myeloma. The agent has been granted fast track
designation by the United States Food and Drug Administration (FDA). Pfizer presented
findings of Elranatamab’s Phase II MagnetisMM-3 study (NCT04649359) at ASCO 2022.
MagnetisMM-3 is a Phase II open-label, multicenter, single-arm trial examining the safety

2. MULTIPLE MYELOMA ASCO CONFERENCE 2022
MULTIPLE MYELOMA
and efficacy of elranatamab monotherapy in patients with relapsed/refractory multiple
myeloma.
Initial efficacy findings of elranatamab showed a 60.6% objective response rate after a
median follow-up of 3.71 months. At the time of the data cut-off, 89.5% of objective
responders were ongoing with no evidence of progression or death.
The safety and effectiveness of 94 patients who had received at least one dose of
elranatamab (Cohort A – BCMA- naïve) as of the data cutoff on March 23, 2022, were
studied in this interim analysis. In patients with triple-class refractory Multiple Myeloma,
the data revealed that 76 mg of elranatamab weekly (QW) might have a tolerable safety
profile. Hematologic adverse events such as anemia, neutropenia, thrombocytopenia,
lymphopenia, and cytokine release syndrome (CRS) were the most prevalent treatment-
emergent adverse events. All CRS were Grade I (40.0%) or II (40.0%) in the 90 individuals
who underwent the 2-step-up priming regimen (18.9%). In addition, ICANS (immune
effector cell-associated neurotoxicity syndrome) affected 2.2% of patients, all of whom
were in Grade 2 or below.
“Bispecific antibodies hold promise as the next breakthrough in treating multiple myeloma.
These data represent an important step forward as we look to bring elranatamab as a
potential innovative new treatment to people living with relapsed or refractory multiple
myeloma, where there is a high need”-Expert Opinion.
“We are encouraged by these early efficacy and safety results, which suggest elranatamab
may have a manageable safety profile coupled with early promising clinical responses. We
look forward to the final analysis from MagnetisMM-3, which is expected later this year.” -
Expert Opinion.
Conclusion: The antibody-drug conjugate (Blenrep) and the FDA-approved CAR T-cell
therapies (Abecma and Carvykti) are the current BCMA-directed choices for heavily
pretreated Multiple Myeloma patients. In the registrational directed Phase II MagnetisMM-
3 trial, Pfizer's BCMA x CD3 bispecific antibody elranatamab demonstrated encouraging
preliminary effectiveness and tolerability. Before this, the company disclosed results from
the phase I MagnetisMM-1 study (NCT03269136), which demonstrated that when
elranatamab was administered in dosages up to 1000 µg/kg, the drug had a tolerable safety
profile with no dose-limiting toxicities (DLT’s) when presented at the 2021 ASCO Annual
Meeting. It is worth noting that the FDA slapped a partial clinical hold on the drug last year
owing to peripheral neuropathy cases. But now, the hold has been lifted.
Along with Pfizer, many companies, including J&J, Roche, Regeneron Pharmaceuticals, and
others, are investigating bispecific antibodies in Multiple Myeloma. Some of the companies
are investigating non-BCMA targets, including FcRH5 and GPRC5D. J&J holds the lead

3. MULTIPLE MYELOMA ASCO CONFERENCE 2022
MULTIPLE MYELOMA
among many bispecific antibodies being explored for Multiple Myeloma. Janssen's
teclistamab is the first BCMA x CD3 bispecific to be filed to the FDA (filing in December
2021) and EMA (filing in January 2022) for approval in Multiple Myeloma. While teclistamab
appears to be on track to become the first BCMA-targeting bispecific antibody to hit the
market, Pfizer's elranatamab is closely following J&J's footsteps. In the registration
MagnetisMM-3 trial, elranatamab was linked with an ORR of 60.6 percent after a median
follow-up of just under four months; on the other hand, teclistamab's MajesTEC-1 study
gave an ORR of 63%. Pfizer’s therapy has a competitive edge in terms of safety profile. The
MagnetisMM-3 data show a 60% rate of CRS, compared to roughly 72% in the teclistamab
trial. Because bispecific antibodies are off-the-shelf, readily available medicines, they are
anticipated to become widely employed in the relapsed/refractory arena. In this area, ADC
and CAR T-cell therapies are already available, but the inclusion of bispecific antibodies may
provide patients with more options (different treatments will be appropriate for different
patients).
Companies- Oncopeptides, GlaxoSmithKline, Bluebird Bio, Janssen Pharmaceutical, Legend
Biotech, AbbVie, Roche (Genentech), Bristol Myers Squibb, Regeneron Pharmaceuticals,
Pfizer, Takeda, Amgen, SpringWorks Therapeutics, Arcellx, Gracell Biotechnologies, Oricell,
Poseida Therapeutics, Precision Biosciences, CRISPR Therapeutics AG, Collectis SA, Allogene
Therapeutics, Fortis Therapeutics, Novartis, I-Mab/MorphoSys, Cartesian Therapeutics, CASI
Pharmaceuticals, LAVA Therapeutics, and others.
To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed
Coverage | ASCO 2022 Conference | ASCO Conference 2022 | ASCO Abstract 2022
Some of the Latest ASCO Abstract 2022 Launched:-
 Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line
setting for the patients with R/R Large B-cell lymphoma (LBCL)?
 Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in
Multiple Myeloma during ASCO 2022.
 Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1
Fusions in Lung and Pancreatic Cancer
Get in touch with our Business Expert- Business Consulting Services | Biotech Consulting
Reactive Airway Disease Market
Reactive Airway Disease Market report delivers an in-depth understanding of the historical
and forecasted epidemiology as well as the market trends in the 7MM

4. MULTIPLE MYELOMA ASCO CONFERENCE 2022
MULTIPLE MYELOMA
Coronary Microvascular Dysfunction CMD Market
DelveInsight’s Coronary Microvascular Dysfunction Market Insights, Epidemiology, &
Market Forecast 2032 report delivers an in-depth understanding of the CMD epidemiology
& CMD market trends
Familial Lipoprotein Lipase Deficiency Pipeline
Familial Lipoprotein Lipase Deficiency Pipeline Insights, 2022 report by DelveInsight outlays
comprehensive insights of present clinical development scenario and growth prospects
across.
Pediatric Growth Hormone Deficiency PGHD Market
Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast
report delivers an understanding of the Pediatric Growth Hormone Deficiency forecasted
epidemiology
Shigellosis Market
DelveInsight’s Shigellosis Market Insights, Epidemiology, and Market Forecast-2032″ report
delivers an in-depth understanding of the Shigellosis, historical and forecasted
epidemiology
About Us
DelveInsight is a Business Consulting and Market research company, providing expert
business solutions for the life science vertical and offering quintessential advisory services
in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence,
Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash
info@delveinsight.com